UPF1 silenced cellular model systems for screening of read-through agents active on β0 39 thalassemia point mutation

BMC Biotechnology
Francesca SalvatoriMonica Borgatti

Abstract

Nonsense mutations promote premature translational termination, introducing stop codons within the coding region of mRNAs and causing inherited diseases, including thalassemia. For instance, in β039 thalassemia the CAG (glutamine) codon is mutated to the UAG stop codon, leading to premature translation termination and to mRNA destabilization through the well described NMD (nonsense-mediated mRNA decay). In order to develop an approach facilitating translation and, therefore, protection from NMD, ribosomal read-through molecules, such as aminoglycoside antibiotics, have been tested on mRNAs carrying premature stop codons. These findings have introduced new hopes for the development of a pharmacological approach to the β039 thalassemia therapy. While several strategies, designed to enhance translational read-through, have been reported to inhibit NMD efficiency concomitantly, experimental tools for systematic analysis of mammalian NMD inhibition by translational read-through are lacking. We developed a human cellular model of the β039 thalassemia mutation with UPF-1 suppressed and showing a partial NMD suppression. This novel cellular model could be used for the screening of molecules exhibiting preferential read-through activity...Continue Reading

References

Jan 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·T RutherfordD J Weatherall
Oct 1, 1981·The Journal of Clinical Investigation·R F TrecartinA Cao
Aug 17, 1999·The Journal of Clinical Investigation·R J Kaufman
May 16, 2000·Biochemical Pharmacology·N BianchiR Gambari
Sep 13, 2002·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Ming DuDavid M Bedwell
Jul 31, 2004·Nature Genetics·Jill A HolbrookAndreas E Kulozik
Jun 6, 2008·Trends in Cell Biology·Lukas Stalder, Oliver Mühlemann
Oct 22, 2008·Trends in Genetics : TIG·Liat Linde, Batsheva Kerem
Jul 25, 2009·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Steven M Rowe, John P Clancy
Nov 14, 2012·Briefings in Functional Genomics·Isabel M Palacios
Apr 2, 2013·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Nicola AltamuraMonica Borgatti
Jan 8, 2016·Organic & Biomolecular Chemistry·Victoria J B GothamIain Coldham
Jul 14, 2016·Nucleic Acids Research·Alireza Baradaran-HeraviMichel Roberge
Dec 3, 2016·Nucleic Acids Research·Rocio T Martinez-NunezJeremy R Sanford

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
Protein Assay
FACS
Transfection

Software Mentioned

Cell Quest Pro
FACScan
Quantity One

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.